Can Simpirica Simplify Spine Stabilization?
Founded at the height of the spine industry’s surge, Simpirica Spine Inc. has developed a dynamic stabilization device that is reminiscent in its simplicity and novelty of past interspinous spacers. The company will soon embark on a 400-patient pivotal trial in the US testing its LimiFlex against posterolateral fusion in treating degenerative spondylolisthesis. A successful outcome in the trial could help offset some of the setbacks the spine industry has suffered over the past five years.
You may also be interested in...
Our data-driven review of the portfolios of more than two dozen leading medical device VCs show that the median life span of venture-backed companies hovers at seven years. Younger medtech companies are getting by – and getting farther in the regulatory process – with less capital, reflecting the current state of an industry that sees a whole lot of belt tightening in its future.
This years’ gathering of the North American Spine Society (NASS) carried a muted tone that befits a stagnant or shrinking industry. Surgeons in NASS’ leadership spoke to the minimal growth in their own reimbursements and their concerns over how changes in the health care sector will impact the specialty going forward.
Increasing concerns over the cost and efficacy of spinal procedures have chilled VC interest in spine companies, once the hot growth area in orthopedics. So, if spine is not the answer, where will VCs find investment opportunities in orthopedics, which remains one of the largest device sectors?